menu
    • menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD4017","moa":"11-beta-hydroxysteroid dehydrogenase 1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"TheiaLife","sponsor":"LifeSci Consulting","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.A.E","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"7-Methylxanthine","moa":"Adenosine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TheiaLife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TheiaLife \/ LifeSci Consulting","highestDevelopmentStatusID":"8","companyTruncated":"TheiaLife \/ LifeSci Consulting"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocugen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocugen \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Visus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Visus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eye Therapies","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eye Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eye Therapies \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Eye Therapies \/ Ora, Inc"},{"orgOrder":0,"company":"Eye Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eye Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eye Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eye Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Alleanza Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ALZ-1101","moa":"Amyloid-beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alleanza Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alleanza Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alleanza Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"GSK933776","moa":"Amyloid-beta A4 protein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"GSK933776","moa":"Amyloid-beta A4 protein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Quintiles Inc"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Trial Runners, LLC | Duke University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allegro Ophthalmics \/ Trial Runners, LLC | Duke University","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Trial Runners, LLC | Duke University"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Duke University | Trial Runners, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Duke University | Trial Runners, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Duke University | Trial Runners, LLC"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Tyrogenex","sponsor":"Syneos Health | International Drug Development Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||Platelet-derived growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tyrogenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyrogenex \/ Syneos Health | International Drug Development Institute","highestDevelopmentStatusID":"8","companyTruncated":"Tyrogenex \/ Syneos Health | International Drug Development Institute"},{"orgOrder":0,"company":"Tyrogenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||Platelet-derived growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tyrogenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyrogenex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tyrogenex \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AnewPharma","sponsor":"Renmin Hospital of Wuhan University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF receptor\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AnewPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AnewPharma \/ Renmin Hospital of Wuhan University","highestDevelopmentStatusID":"8","companyTruncated":"AnewPharma \/ Renmin Hospital of Wuhan University"},{"orgOrder":0,"company":"AnewPharma","sponsor":"West China Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF receptor\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AnewPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AnewPharma \/ West China Hospital","highestDevelopmentStatusID":"8","companyTruncated":"AnewPharma \/ West China Hospital"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Equinox Science","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Equinox Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equinox Science \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Equinox Science \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"REGN910-3","moa":"Angiopoietin-2 (ANGPT2)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"REGN910-3","moa":"Angiopoietin-2 (ANGPT2)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"REGN910-3","moa":"Angiopoietin-2 (ANGPT2)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Greater Houston Retina Research","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Greater Houston Retina Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Greater Houston Retina Research \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Greater Houston Retina Research \/ Genentech"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bromfenac Sodium Salt Sesquihydrate","moa":"anti-inflammatory agents (acetic acid derivatives)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Redwood Pharma","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brivudine","moa":"antineoplastics","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Redwood Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Redwood Pharma \/ Cross Research S.A.","highestDevelopmentStatusID":"8","companyTruncated":"Redwood Pharma \/ Cross Research S.A."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Combretastatin A-4 Phosphate","moa":"antineoplastics (mitotic inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mateon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Zinpentraxin Alfa","moa":"APCS","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Lexitas","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Lexitas","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Lexitas"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Hong Kong Polytechnic University","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hong Kong Polytechnic University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hong Kong Polytechnic University \/ Alcon Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hong Kong Polytechnic University \/ Alcon Inc"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Keyrus Biopharma | VEEDA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratoires Thea \/ Keyrus Biopharma | VEEDA","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Keyrus Biopharma | VEEDA"},{"orgOrder":0,"company":"Philadelphia Eye Associates","sponsor":"Merck & Co | Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Philadelphia Eye Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philadelphia Eye Associates \/ Merck & Co | Thomas Jefferson University","highestDevelopmentStatusID":"8","companyTruncated":"Philadelphia Eye Associates \/ Merck & Co | Thomas Jefferson University"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Hovione Scientia Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione Scientia Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Hovione Scientia Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hovione Scientia Limited \/ Undisclosed"},{"orgOrder":0,"company":"Hovione","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PORTUGAL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Hovione \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hovione \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Unity Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Unity Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Unity Biotechnology"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Betaliq","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BTQ-1901-A","moa":"Beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betaliq \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ Undisclosed"},{"orgOrder":0,"company":"Betaliq","sponsor":"Trial Runners, LLC | Summit Analytical LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betaliq \/ Trial Runners, LLC | Summit Analytical LLC","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ Trial Runners, LLC | Summit Analytical LLC"},{"orgOrder":0,"company":"Invirsa","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Invirsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Undisclosed"},{"orgOrder":0,"company":"Invirsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Undisclosed"},{"orgOrder":0,"company":"Invirsa","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Invirsa","sponsor":"Cincytech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Cincytech","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Cincytech"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"Bamosiran","moa":"Beta-2 adrenergic receptor mRNA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"SYL040012","moa":"Beta-2 adrenergic receptor mRNA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"FOV2304","moa":"Bradykinin B1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Elamipretide HCl","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mitotech","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mitotech \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Mitotech \/ Ora, Inc"},{"orgOrder":0,"company":"Quark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"QPI-1007","moa":"Caspase 2 messenger RNA (CASP2 mRNA)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Quark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"SBI-100","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PF-04634817","moa":"C-C chemokine receptor type 2 | C-C chemokine receptor type 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AKST4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ALK4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ALK4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"BI144807","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"MT-0814","moa":"CCR3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ PPD"},{"orgOrder":0,"company":"Hemera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AAVCAGsCD59","moa":"CD59","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hemera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hemera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"IONIS-FB-LRx","moa":"CFB messenger RNA (CFB mRNA)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"IONIS-FB-LRx","moa":"CFB messenger RNA (CFB mRNA)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"OK-101","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Ora, Inc"},{"orgOrder":0,"company":"Eurobio Scientific","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"AGN-231868","moa":"Chemokine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eurobio Scientific","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Eurobio Scientific \/ Allergan Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Eurobio Scientific \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TP-03","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TP-03","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"YD312","moa":"c-Kit","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"YD Life Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Funding","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Tufts Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Tufts Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Tufts Medical Center"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ AmbioPharm","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ AmbioPharm"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"StemCells, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"HuCNS-SC","moa":"CNS cells","graph1":"Ophthalmology","graph2":"Phase II","graph3":"StemCells, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCells, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"StemCells, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Microplasmin","moa":"Collagen | Fibronectin | Laminin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"ForSeeCon Eye Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1701","moa":"Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ ForSeeCon Eye Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ ForSeeCon Eye Corporation"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AL-78898A","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AL-78898A","moa":"Complement C3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Expanded Collaboration","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tesidolumab","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IVERIC bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IVERIC bio \/ Undisclosed"},{"orgOrder":0,"company":"Ophthotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ophthotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ophthotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophthotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Ophthotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ophthotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ophthotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophthotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Ophthotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ophthotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ophthotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophthotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Danicopan","moa":"Complement factor D","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"FCFD4514S","moa":"Complement factor D","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Lampalizumab","moa":"Complement factor D","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Lampalizumab","moa":"Complement factor D","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GEM103","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GEM103","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GEM103","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Fs Development Corp","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Fs Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Fs Development Corp"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.5,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Acquisition","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.5,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"CLG561","moa":"Complement factor P (CFP)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alcon Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"L.V. Prasad Eye Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nepafenac","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"L.V. Prasad Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"L.V. Prasad Eye Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"L.V. Prasad Eye Institute \/ Allergan"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Apexian Pharmaceuticals","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Apexian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apexian Pharmaceuticals \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Apexian Pharmaceuticals \/ Ocuphire Pharma"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opus Genetics \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Opus Genetics \/ Ocuphire Pharma"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opus Genetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Opus Genetics \/ Undisclosed"},{"orgOrder":0,"company":"Snyder, Robert W., M.D., Ph.D., P.C.","sponsor":"Snyder Biomedical Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Snyder, Robert W., M.D., Ph.D., P.C.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Snyder, Robert W., M.D., Ph.D., P.C. \/ Snyder Biomedical Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Snyder, Robert W., M.D., Ph.D., P.C. \/ Snyder Biomedical Corporation"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Endoglin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"DE-122","moa":"Endoglin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"DE-122","moa":"Endoglin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Curacle","sponsor":"Th\u00e9a Open Innovation, France","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CU06-1004","moa":"Endothelial cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curacle","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Curacle \/ Th\u00e9a Open Innovation, France","highestDevelopmentStatusID":"8","companyTruncated":"Curacle \/ Th\u00e9a Open Innovation, France"},{"orgOrder":0,"company":"Curacle","sponsor":"KCRN Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CU06-1004","moa":"Endothelial cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curacle","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Curacle \/ KCRN Research","highestDevelopmentStatusID":"8","companyTruncated":"Curacle \/ KCRN Research"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perfuse Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perfuse Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LKA651","moa":"Erythropoietin (EPO)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"LKA651","moa":"Erythropoietin (EPO)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Amgen Inc"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RBM-007","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"RBM-007","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ribomic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Aju Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Aju Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Aju Pharma"},{"orgOrder":0,"company":"Ribomic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Midwest Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Midwest Eye Institute","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Midwest Eye Institute"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Udonitrectag","moa":"FGFR4","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Recordati Rare Diseases \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Recordati Rare Diseases \/ Syneos Health"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Ocriplasmin","moa":"Fibronectin | Collagen | Laminin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Ocriplasmin","moa":"Fibronectin | Collagen | Laminin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stanford University \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"The Emmes Company, LLC | Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Eye Institute \/ The Emmes Company, LLC | Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Eye Institute \/ The Emmes Company, LLC | Santen Pharmaceutical"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"LL-BMT1","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"IUVO","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"PA5108","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ IUVO","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ IUVO"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"PA5108","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"D-4517.2","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"D-4517.2","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Tribe Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Series B Financing","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Tribe Capital","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Tribe Capital"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RG7774","moa":"FXR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Neuroptika","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NRO-1","moa":"GDNFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroptika \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika \/ Undisclosed"},{"orgOrder":0,"company":"Neuroptika","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NRO-1","moa":"GDNFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroptika \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PF-04382923","moa":"GHS receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Surface Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Surface Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"SURF-201","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"AR-1105 Implant","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BOL-303242-X","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Icon Bioscience Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Icon Bioscience Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Bioscience Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Icon Bioscience Inc \/ Undisclosed"},{"orgOrder":0,"company":"Icon Bioscience Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Icon Bioscience Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Bioscience Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Icon Bioscience Inc \/ Undisclosed"},{"orgOrder":0,"company":"iDrop","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NORWAY","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iDrop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"iDrop \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iDrop \/ Undisclosed"},{"orgOrder":0,"company":"Oxular","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection, Sustained Release","sponsorNew":"Oxular \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Forbion"},{"orgOrder":0,"company":"Oxular","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Oxular \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Retinal Consultants of Arizona","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Retinal Consultants of Arizona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Retinal Consultants of Arizona \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Retinal Consultants of Arizona \/ Allergan"},{"orgOrder":0,"company":"Retina Macula Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Retina Macula Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Retina Macula Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Retina Macula Institute \/ Allergan"},{"orgOrder":0,"company":"McMaster University","sponsor":"Hamilton Health Sciences | St. Joseph's Healthcare Hamilton","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"McMaster University \/ Hamilton Health Sciences | St. Joseph's Healthcare Hamilton","highestDevelopmentStatusID":"8","companyTruncated":"McMaster University \/ Hamilton Health Sciences | St. Joseph's Healthcare Hamilton"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2020","type":"Series A Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Ripple Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ripple Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pradeepa Yoganathan","sponsor":"Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pradeepa Yoganathan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pradeepa Yoganathan \/ Unity Health Toronto","highestDevelopmentStatusID":"8","companyTruncated":"Pradeepa Yoganathan \/ Unity Health Toronto"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"NR3C1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"NR3C1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eclipse Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Price Vision Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Fluorometholone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Price Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Price Vision Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Price Vision Group \/ Undisclosed"},{"orgOrder":0,"company":"Nicox Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Koffler Vision Group","sponsor":"Fera Pharmaceuticals, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Koffler Vision Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Koffler Vision Group \/ Fera Pharmaceuticals, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Koffler Vision Group \/ Fera Pharmaceuticals, LLC"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch & Lomb Incorporated \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Syneos Health"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Nicox Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"NCX 4251","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"OTX-DED","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"OTX-DED","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Oxular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"OXU-001","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Oxular \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Undisclosed"},{"orgOrder":0,"company":"Oxular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxular \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DE-110","moa":"GR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST-100","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stuart Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Stuart Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Quark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"PF-04523655","moa":"HIF-1 responsive protein RTP801 (DDIT4)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Quark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Quark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Galegenimab","moa":"HTRA1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Galegenimab","moa":"HTRA1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Etafilcon A","moa":"hydrophilic contact lens materials","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vamikibart","moa":"IL6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vamikibart","moa":"IL6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Sanhuangjingshimingwan","moa":"Immune","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Silk Technologies, Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"SDP-4","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Silk Technologies, Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Silk Technologies, Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silk Technologies, Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Silk Technologies, Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SDP-4","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Silk Technologies, Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Silk Technologies, Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silk Technologies, Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Belfast Health and Social Care Trust","sponsor":"Araim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Belfast Health and Social Care Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belfast Health and Social Care Trust \/ Araim Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Belfast Health and Social Care Trust \/ Araim Pharmaceuticals"},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Araim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Araim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Surface Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"rhIGF-I\/rhIGFBP-3","moa":"Insulin-like growth factor I receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OTT166","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Parexel"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Kreos Capital","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Kreos Capital"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ AyurMaya"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Andover Eye Associates","sponsor":"Statistics & Data Corporation | Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Andover Eye Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andover Eye Associates \/ Statistics & Data Corporation | Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Andover Eye Associates \/ Statistics & Data Corporation | Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Ophthalmology","graph2":"Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Nebraska \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska \/ Genentech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"R348","moa":"Janus kinase 3 (JAK-3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"R348","moa":"Janus kinase 3 (JAK-3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xigen SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"XG-104","moa":"JNK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Xigen SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xigen SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xigen SA \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Latanoprost","moa":"||KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Canaan Partners","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Canaan Partners"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Darapladib","moa":"LDL-associated phospholipase A2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"UNR844","moa":"Lens protein disulfide bonds","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"UNR844-Cl","moa":"Lens protein disulfide bonds","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BIIB033","moa":"Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BIIB033","moa":"Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BI1467335","moa":"MAO-B\/VAP-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Curatis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Undisclosed"},{"orgOrder":0,"company":"Curatis","sponsor":"Great Health Companion Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Great Health Companion Group","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Great Health Companion Group"},{"orgOrder":0,"company":"Curatis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Palatin Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Palatin Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Palatin Technologies"},{"orgOrder":0,"company":"Metropolitan Eye Research & Surgery Institute","sponsor":"Mallinckrodt Pharmaceuticals | Stanford University | Ocular Imaging Research and Reading Center | Foresight Studies","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Metropolitan Eye Research & Surgery Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metropolitan Eye Research & Surgery Institute \/ Mallinckrodt Pharmaceuticals | Stanford University | Ocular Imaging Research and Reading Center | Foresight Studies","highestDevelopmentStatusID":"8","companyTruncated":"Metropolitan Eye Research & Surgery Institute \/ Mallinckrodt Pharmaceuticals | Stanford University | Ocular Imaging Research and Reading Center | Foresight Studies"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Pharmaxis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BI 1467335","moa":"Membrane copper amine oxidase (AOC3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Pharmaxis","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Pharmaxis"},{"orgOrder":0,"company":"Hemera Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"HMR59","moa":"Membrane inhibitor of reactive lysis (CD59)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hemera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemera Biosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hemera Biosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wagner Macula & Retina Center","sponsor":"Oxurion","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Wagner Macula & Retina Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wagner Macula & Retina Center \/ Oxurion","highestDevelopmentStatusID":"8","companyTruncated":"Wagner Macula & Retina Center \/ Oxurion"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"San Francisco Veterans Affairs Medical Center | VA Palo Alto Health Care System | University of California, Davis | University of California, San Diego | Northwestern University | University of Illinois, Chicago | Retinal Consultants Medical Group | Retin","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ San Francisco Veterans Affairs Medical Center | VA Palo Alto Health Care System | University of California, Davis | University of California, San Diego | Northwestern University | University of Illinois, Chicago | Retinal Consultants Medical Group | Retin","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ San Francisco Veterans Affairs Medical Center | VA Palo Alto Health Care System | University of California, Davis | University of California, San Diego | Northwestern University | University of Illinois, Chicago | Retinal Consultants Medical Group | Retin"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Avania","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Avania","highestDevelopmentStatusID":"8","companyTruncated":"Azura Ophthalmics \/ Avania"},{"orgOrder":0,"company":"Beijing Anlong Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AL-001","moa":"monoclonal antibodies: neural","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Beijing Anlong Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Anlong Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Anlong Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Anlong Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AL-001","moa":"monoclonal antibodies: neural","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Beijing Anlong Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Anlong Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Anlong Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Glaukos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glaukos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glaukos \/ Undisclosed"},{"orgOrder":0,"company":"Glaukos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glaukos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glaukos \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AGN-190584","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Simpinicline","moa":"Neuronal acetylcholine receptor; alpha3\/beta4 | Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACT-01","moa":"Neurotrophic factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Accure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dompe Farmaceutici \/ Cross Research S.A.","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Cross Research S.A."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rebamipide","moa":"Muscarinic receptor||N-formyl peptide receptor (FPR1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rebamipide","moa":"N-formyl peptide receptor (FPR1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Kubota Pharmaceutical \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Kubota Pharmaceutical \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aperta Biosciences, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aperta Biosciences, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Aperta Biosciences, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aperta Biosciences, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AGN-210961","moa":"non-prostanoid prostaglandin receptor agonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biogen \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Biogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biogen \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Ophthotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"Pegpleranib","moa":"PDGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ophthotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ophthotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophthotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Financing","leadProduct":"Elamipretide","moa":"peptides","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rivoglitazone Hydrochloride","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rivoglitazone Hydrochloride","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BI1584862","moa":"Phospholipid","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"THR-317","moa":"Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"THR-317","moa":"Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"KVD001","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KalVista Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Juvenile Diabetes Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"KVD001","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KalVista Pharmaceuticals \/ Juvenile Diabetes Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Juvenile Diabetes Research Foundation"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"KVD001","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.76000000000000001,"dosageForm":"Injection","sponsorNew":"KalVista Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Termination","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Funding","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Bank Degroof Petercam","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Bank Degroof Petercam"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Oxurion \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ VIB"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"Ophthotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"E10030","moa":"Platelet-derived growth factor subunit B","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ophthotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ophthotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophthotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Ophthotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"Pegpleranib Sodium","moa":"Platelet-derived growth factor subunit B","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ophthotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ophthotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ophthotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"||Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Fondazione Policlinico Universitario Agostino Gemelli","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cord Blood Cell","moa":"Progenitor cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Fondazione Policlinico Universitario Agostino Gemelli","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Policlinico Universitario Agostino Gemelli \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"8","companyTruncated":"Fondazione Policlinico Universitario Agostino Gemelli \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"SIFI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Undisclosed"},{"orgOrder":0,"company":"SIFI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Undisclosed"},{"orgOrder":0,"company":"Signal 12","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Signal 12","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Signal 12 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Signal 12 \/ Undisclosed"},{"orgOrder":0,"company":"Pharmadax","sponsor":"Glia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Pro-Ocular","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharmadax \/ Glia","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Glia"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Danazol","moa":"Progesterone receptor | Androgen Receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Danazol","moa":"Progesterone receptor | Androgen Receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ampio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Isopropyl Unoprostone","moa":"prostaglandins","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Sucampo Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AGN-210669","moa":"Prostanoid EP2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sepetaprost","moa":"Prostanoid EP3 receptor | Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sepetaprost","moa":"Prostanoid EP3 receptor | Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sepetaprost","moa":"Prostanoid EP3 receptor | Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sepetaprost","moa":"Prostanoid EP3 receptor | Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Series A Financing","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"ForSight Vision5","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ForSight Vision5","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"ForSight Vision5 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ForSight Vision5 \/ Undisclosed"},{"orgOrder":0,"company":"ForSight Vision5","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ForSight Vision5","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"ForSight Vision5 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ForSight Vision5 \/ Undisclosed"},{"orgOrder":0,"company":"ForSight Vision5","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ForSight Vision5","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"ForSight Vision5 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ForSight Vision5 \/ Undisclosed"},{"orgOrder":0,"company":"ForSight Vision5","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ForSight Vision5","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"ForSight Vision5 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ForSight Vision5 \/ Undisclosed"},{"orgOrder":0,"company":"ForSight Vision5","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ForSight Vision5","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"ForSight Vision5 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ForSight Vision5 \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"KALA Bio \/ SR One Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One Capital Management"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"KALA Bio \/ SR One Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One Capital Management"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Kala Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kala Pharmaceuticals \/ Kala Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Kala Pharmaceuticals"},{"orgOrder":0,"company":"Okogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"OKG-0301","moa":"Protein Biosynthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Okogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Okogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Okogen \/ Undisclosed"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diquafosol Sodium","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RCI001","moa":"RAC1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Juvenile Diabetes Research Foundation | iCo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"iCo-007","moa":"Raf messenger RNA (Raf mRNA)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Juvenile Diabetes Research Foundation | iCo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Juvenile Diabetes Research Foundation | iCo Therapeutics"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aadi Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lpath","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lpath","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lpath \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lpath \/ Undisclosed"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"Retinoid isomerohydrolase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kubota Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kubota Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DE-120","moa":"Rho kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DE-120","moa":"Rho kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Amakem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AMA0076","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amakem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amakem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amakem \/ Undisclosed"},{"orgOrder":0,"company":"Amakem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AMA0076","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amakem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amakem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amakem \/ Undisclosed"},{"orgOrder":0,"company":"Amakem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AMA0076","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amakem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amakem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amakem \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AR-12286","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AR-12286","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AR-12286","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AR-12286","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AURN001","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AURN001","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"pH Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"PHP-201","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"pH Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"pH Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"pH Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nvision Laser Eye Centers","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nvision Laser Eye Centers","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Nvision Laser Eye Centers \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nvision Laser Eye Centers \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","sponsor":"H\u00f4pital Universitaire Robert-Debr\u00e9 | Institut National de la Transfusion Sanguine | Keyrus Biopharma | For Drug Consulting | Theravia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts \/ H\u00f4pital Universitaire Robert-Debr\u00e9 | Institut National de la Transfusion Sanguine | Keyrus Biopharma | For Drug Consulting | Theravia","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts \/ H\u00f4pital Universitaire Robert-Debr\u00e9 | Institut National de la Transfusion Sanguine | Keyrus Biopharma | For Drug Consulting | Theravia"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ABBV-RGX-314","moa":"RNA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Regenxbio"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VVN539","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VVN539","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"D. Western Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"H-1337","moa":"ROCK\/AKT\/PDK1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"D. Western Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"D. Western Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"D. Western Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"D. Western Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"H-1337","moa":"ROCK\/AKT\/PDK1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"D. Western Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"D. Western Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"D. Western Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CNTO 2476","moa":"RPE65","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CNTO 2476","moa":"RPE65","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI 764524","moa":"Semaphorin-3A (SEMA3A)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Neurotrials","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oculis \/ Neurotrials","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Neurotrials"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BofA Securities"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CT1812","moa":"Sigma intracellular receptor 2 (TMEM97)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CT1812","moa":"Sigma intracellular receptor 2 (TMEM97)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elman Retina Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Squalamine Lactate","moa":"Sodium\/hydrogen exchanger 3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Elman Retina Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Elman Retina Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elman Retina Group \/ Undisclosed"},{"orgOrder":0,"company":"Ohr Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Squalamine Lactate","moa":"Sodium\/hydrogen exchanger 3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ohr Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ohr Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ohr Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Runcaciguat","moa":"Soluble guanylate cyclase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YD Life Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Undisclosed"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IC265","moa":"Syk","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IACTA Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DT-168","moa":"TCF4 gene expression","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Design Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Design Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DT-168","moa":"TCF4 gene expression","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Design Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Design Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"C.T. Development America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"RX-10045","moa":"TGF-beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"C.T. Development America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"C.T. Development America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"C.T. Development America \/ Undisclosed"},{"orgOrder":0,"company":"C.T. Development America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"RX-10045","moa":"TGF-beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"C.T. Development America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"C.T. Development America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"C.T. Development America \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ozagrel Sodium","moa":"Thromboxane-A synthase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ozagrel Sodium","moa":"Thromboxane-A synthase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ozagrel Sodium","moa":"Thromboxane-A synthase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ozagrel Sodium","moa":"Thromboxane-A synthase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"hI-con1","moa":"tissue factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Iconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ICON-1","moa":"Tissue factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Iconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iconic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iconic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ISV 101","moa":"TLR7","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oregon Health and Science University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Oregon Health and Science University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oculis","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oculis \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Ora, Inc"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"BBA\/\/Fjeldco","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Oculis \/ BBA\/\/Fjeldco","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BBA\/\/Fjeldco"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Oculis","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AGC Biologics \/ Oculis","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biologics \/ Oculis"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ESBA105","moa":"TNF-?","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"EYS606","moa":"TNF-alpha receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyevensys \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eyevensys \/ Undisclosed"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"EYS606","moa":"TNF-alpha receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eyevensys","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Eyevensys \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Eyevensys \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"OcuCure Therapeutics","sponsor":"Semler Research Center Pvt. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"OC-10X","moa":"Tubulin receptor (TUBR)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuCure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OcuCure Therapeutics \/ Semler Research Center Pvt. Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"OcuCure Therapeutics \/ Semler Research Center Pvt. Ltd."},{"orgOrder":0,"company":"OcuCure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"OC-10X","moa":"Tubulin receptor (TUBR)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuCure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OcuCure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuCure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Filgotinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PRO-155","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"Ocuwize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuwize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuwize \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuwize \/ Undisclosed"},{"orgOrder":0,"company":"Ocuwize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuwize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuwize \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuwize \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"601","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Dompe Farmaceutici","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Safar Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Safar Partners"},{"orgOrder":0,"company":"Aciex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AC-150","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aciex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aciex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aciex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ADX-038","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allgenesis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Lexitas","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Lexitas","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Lexitas"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Allgenesis Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"AG-86893","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AGN-195263","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AGN-223575","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"AL-53817","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AL-54478","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AL-59412C","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Alzer Y Diamel","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Amydis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMDX-2011P","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amydis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amydis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amydis \/ Undisclosed"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Annexin A5","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Annexin A5","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"InFocus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANXV","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annexin Pharmaceuticals \/ InFocus Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ InFocus Clinical Research"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AR-17043","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Altheos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ATS907","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Altheos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altheos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altheos \/ Undisclosed"},{"orgOrder":0,"company":"Altheos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ATS907","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Altheos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altheos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altheos \/ Undisclosed"},{"orgOrder":0,"company":"AxeroVision","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"AXR-159","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AxeroVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AxeroVision \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"AxeroVision \/ Ora, Inc"},{"orgOrder":0,"company":"AxeroVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AXR-270","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AxeroVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AxeroVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AxeroVision \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BI 1026706","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BI 1584862","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BI1815368","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI764524","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BI764524","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"BRIM Biotechnology Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BRM424","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"BRIM Biotechnology Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRIM Biotechnology Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRIM Biotechnology Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Biotheravision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BTV100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Biotheravision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biotheravision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotheravision \/ Undisclosed"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CBT-004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cloudbreak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cloudbreak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CBT-006","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cloudbreak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cloudbreak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CBT-008","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cloudbreak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cloudbreak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FINLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Cis-UCA","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Herantis Pharma \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Herantis Pharma \/ Ora, Inc"},{"orgOrder":0,"company":"Glia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CLM2","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glia \/ Undisclosed"},{"orgOrder":0,"company":"Deacon Biosciences","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DCN01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Deacon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Deacon Biosciences \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Deacon Biosciences \/ Ora, Inc"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DE-127","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"EyebioKorea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EB-203","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyebioKorea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyebioKorea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyebioKorea \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ECF843","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EG017","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EG-301","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evergreen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EnnovaBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ENN0403","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EnnovaBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnnovaBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EnnovaBio \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"EYN-1601","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Glia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GL101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glia \/ Undisclosed"},{"orgOrder":0,"company":"GL Pharm Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GLH8NDE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GL Pharm Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GL Pharm Tech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GL Pharm Tech \/ Undisclosed"},{"orgOrder":0,"company":"GL Pharm Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GLH8NDE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GL Pharm Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GL Pharm Tech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GL Pharm Tech \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GV550","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hemigalactarate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HU00701","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Membrane","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Iolyx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ILYX-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Iolyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Iolyx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iolyx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intratus","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"INT-11P001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Intratus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intratus \/ Glaukos","highestDevelopmentStatusID":"8","companyTruncated":"Intratus \/ Glaukos"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-81201887","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JNJ-81201887","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Research Institute, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"K-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kowa Research Institute, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kowa Research Institute, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Research Institute, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Keluo Xin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KIO-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KIO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KIO-201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"YUNGJIN PHARM. CO. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KL7016","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YUNGJIN PHARM. CO. LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YUNGJIN PHARM. CO. LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"YUNGJIN PHARM. CO. LTD \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LHA510","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"LME636","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"LME636","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amber Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Lufepirsen","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amber Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amber Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amber Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Amber Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Lufepirsen","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amber Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amber Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amber Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Innostellar Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LX102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innostellar Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innostellar Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innostellar Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innostellar Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LX102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innostellar Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innostellar Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innostellar Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"MA09-hRPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"MA09-hRPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"MA09-hRPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"MA09-hRPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Theratocular Biotek Co.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MG-O-1002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Theratocular Biotek Co.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theratocular Biotek Co. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theratocular Biotek Co. \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Novelia","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Lublin","sponsor":"Aeon Astron Europe B.V.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ologen","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Medical University of Lublin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Medical University of Lublin \/ Aeon Astron Europe B.V.","highestDevelopmentStatusID":"8","companyTruncated":"Medical University of Lublin \/ Aeon Astron Europe B.V."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"OT202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"P-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"P-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Parion Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"P-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Parion Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Parion Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Parion Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PG286","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Peregrine Ophthalmic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"POLAT-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Peregrine Ophthalmic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peregrine Ophthalmic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peregrine Ophthalmic \/ Undisclosed"},{"orgOrder":0,"company":"Realm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PR013","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Realm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Realm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Realm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PRT-2761","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"PRX-100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LENZ Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Smilebiotek Zhuhai Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QA102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Smilebiotek Zhuhai Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Smilebiotek Zhuhai Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Smilebiotek Zhuhai Limited \/ Undisclosed"},{"orgOrder":0,"company":"Smilebiotek Zhuhai Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QA102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Smilebiotek Zhuhai Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Smilebiotek Zhuhai Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Smilebiotek Zhuhai Limited \/ Undisclosed"},{"orgOrder":0,"company":"Smilebiotek Zhuhai Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QA108","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Smilebiotek Zhuhai Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smilebiotek Zhuhai Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Smilebiotek Zhuhai Limited \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu University of Traditional Chinese Medicine","sponsor":"Chongqing Taiji Group of Fuling Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Qideng Mingmu","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Chengdu University of Traditional Chinese Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu University of Traditional Chinese Medicine \/ Chongqing Taiji Group of Fuling Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu University of Traditional Chinese Medicine \/ Chongqing Taiji Group of Fuling Pharmaceutical"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RC28-E","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Recoflavone","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Recoflavone","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Recombinant Human IGF-1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"REGN2176-3","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"REGN2176-3","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Raymon Pharmaceuticals Company, Ltd.","sponsor":"WuXi Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RMP-A03","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Suzhou Raymon Pharmaceuticals Company, Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Raymon Pharmaceuticals Company, Ltd. \/ WuXi Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Raymon Pharmaceuticals Company, Ltd. \/ WuXi Clinical"},{"orgOrder":0,"company":"Regenera Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"RPh201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenera Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenera Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenera Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Regenera Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"RPh201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenera Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenera Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenera Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Samjin pharm Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SA001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Samjin pharm Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Samjin pharm Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Samjin pharm Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BRAZIL","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"SATURNO II Association","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"SCAI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SCAI-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SCAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCAI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SCAI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sacsh","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCH-1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sacsh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sacsh \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sacsh \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Sclerfix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Patch","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Sunhawk Vision Biotech, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sunhawk Vision Biotech, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunhawk Vision Biotech, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunhawk Vision Biotech, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Sunhawk Vision Biotech, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sunhawk Vision Biotech, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunhawk Vision Biotech, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunhawk Vision Biotech, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Dreamhawk Vision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dreamhawk Vision Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dreamhawk Vision Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dreamhawk Vision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Samjin pharm Co. Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SJP002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Samjin pharm Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samjin pharm Co. Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Samjin pharm Co. Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SPARC1102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sun Pharma Advanced Research Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma Advanced Research Company \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"ActualEyes","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STN1010904","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ ActualEyes","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ ActualEyes"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STN1013600","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"STSP-0902","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"STSP-0902","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Synletis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SYL1801","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Synletis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synletis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synletis \/ Undisclosed"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SYL1801","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"T1210","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"T4090","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Kukje Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TFC-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kukje Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kukje Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kukje Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Thymosin Beta-4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ReGenTree \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"ReGenTree \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Topivert Pharma Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TOP1630","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Topivert Pharma Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Topivert Pharma Ltd"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TTAX03","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"TissueTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TTBT01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TissueTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TissueTech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TissueTech \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VSJ-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VSJ-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vantage Biosciences","sponsor":"Vantage Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VX-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vantage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vantage Biosciences \/ Vantage Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vantage Biosciences \/ Vantage Biosciences"},{"orgOrder":0,"company":"Vantage Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VX-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vantage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vantage Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vantage Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"IBE-814","moa":"Unknown","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ripple Therapeutics \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SAF312","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SAF312","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"SYL1001","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"SYL1001","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"SYL1001","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Winston Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Zucapsaicin","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Winston Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Winston Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Winston Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abicipar Pegol","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"AGN-150998","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Moorfields Eye Hospital NHS Foundation Trust","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Moorfields Eye Hospital NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moorfields Eye Hospital NHS Foundation Trust \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Moorfields Eye Hospital NHS Foundation Trust \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"Allergan | Genentech | National Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaeb Center for Health Research \/ Allergan | Genentech | National Eye Institute","highestDevelopmentStatusID":"8","companyTruncated":"Jaeb Center for Health Research \/ Allergan | Genentech | National Eye Institute"},{"orgOrder":0,"company":"Retina Vitreous Associates of Florida","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Retina Vitreous Associates of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Retina Vitreous Associates of Florida \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Retina Vitreous Associates of Florida \/ Genentech"},{"orgOrder":0,"company":"Southeast Clinical Research Associates, LLC","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Southeast Clinical Research Associates, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Southeast Clinical Research Associates, LLC \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Southeast Clinical Research Associates, LLC \/ Genentech"},{"orgOrder":0,"company":"Vitreo-Retinal Associates, PC","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vitreo-Retinal Associates, PC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vitreo-Retinal Associates, PC \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Vitreo-Retinal Associates, PC \/ Genentech"},{"orgOrder":0,"company":"Greater Houston Retina Research","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Greater Houston Retina Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Greater Houston Retina Research \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Greater Houston Retina Research \/ Genentech"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Eye Institute \/ The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"National Eye Institute \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Moorfields Eye Hospital NHS Foundation Trust","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Moorfields Eye Hospital NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moorfields Eye Hospital NHS Foundation Trust \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Moorfields Eye Hospital NHS Foundation Trust \/ Bayer AG"},{"orgOrder":0,"company":"Stanford University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stanford University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Wills Eye Hospital","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Wills Eye Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wills Eye Hospital \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Wills Eye Hospital \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyoto Drug Discovery & Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KUS121","moa":"VCP\/p97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyoto Drug Discovery & Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyoto Drug Discovery & Development \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyoto Drug Discovery & Development \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kanghong Biotech","sponsor":"Beijing DMS Pharma | The Digital Angiography Reading Center","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"KH902","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Chengdu Kanghong Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Kanghong Biotech \/ Beijing DMS Pharma | The Digital Angiography Reading Center","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Kanghong Biotech \/ Beijing DMS Pharma | The Digital Angiography Reading Center"},{"orgOrder":0,"company":"Chengdu Kanghong Biotech","sponsor":"University of Wisconsin, Madison | Air Force Military Medical University, China","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"KH902","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Chengdu Kanghong Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Kanghong Biotech \/ University of Wisconsin, Madison | Air Force Military Medical University, China","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Kanghong Biotech \/ University of Wisconsin, Madison | Air Force Military Medical University, China"},{"orgOrder":0,"company":"AngioLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AngioLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AngioLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AngioLab \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efdamrofusp Alfa","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IBI302","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Sierra Eye Associates","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sierra Eye Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sierra Eye Associates \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"Sierra Eye Associates \/ Regenxbio"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":1.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.75,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Regenxbio"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":1.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.75,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"GB-102","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"GB-102","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"GB-102","moa":"VEGF\/PDGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KHK4951","moa":"VEGF1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KHK4951","moa":"VEGF1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KHK4951","moa":"VEGF1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADVM-022","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"ADVM-022","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADVM-022","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SB11","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-150","moa":"VEGF-A\/VEGF-B\/VEGF-C\/PlGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"4D-150","moa":"VEGF-A\/VEGF-B\/VEGF-C\/PlGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Cxlusa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cxlusa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cxlusa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cxlusa \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipe","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BL1107","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"T1695","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VSJ-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciNeuro Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciNeuro Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"APL-3007","moa":"Coagulation factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apellis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Sandeep Jain, MD","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocugen \/ Sandeep Jain, MD","highestDevelopmentStatusID":"8","companyTruncated":"Ocugen \/ Sandeep Jain, MD"},{"orgOrder":0,"company":"Oculis","sponsor":"Quan Dong Nguyen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"OCS-01","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oculis \/ Quan Dong Nguyen","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Quan Dong Nguyen"},{"orgOrder":0,"company":"Argenx","sponsor":"Anastasia Vishnevetsky, MD, MPH","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alfa","moa":"IgG receptor FcRn large subunit p51","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Anastasia Vishnevetsky, MD, MPH","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Anastasia Vishnevetsky, MD, MPH"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Quan Dong Nguyen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Quan Dong Nguyen","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Quan Dong Nguyen"},{"orgOrder":0,"company":"Ohr Pharmaceutical","sponsor":"Starr Muscle","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Squalamine Lactate","moa":"Sodium\/hydrogen exchanger 3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ohr Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ohr Pharmaceutical \/ Starr Muscle","highestDevelopmentStatusID":"8","companyTruncated":"Ohr Pharmaceutical \/ Starr Muscle"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Gerhard Garhofer","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Chitosan Hydrochloride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Croma-Pharma \/ Gerhard Garhofer","highestDevelopmentStatusID":"8","companyTruncated":"Croma-Pharma \/ Gerhard Garhofer"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Amy C Schefler","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Amy C Schefler","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Amy C Schefler"}]

    Find Ophthalmology Drugs in Phase II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evergreen Therapeutics

                            Country
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG-301

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety and Efficacy of EG-301 in Patients with Nonfocal Geographic Atrophy Secondary to DAMD

                            Details : EG-301 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 27, 2021

                            Lead Product(s) : EG-301

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RGX-314

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

                            Details : RGX-314 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wet Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 06, 2021

                            Lead Product(s) : RGX-314

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-RGX-314

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Regenxbio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) ...

                            Details : ABBV-RGX-314 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Retinopathy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : ABBV-RGX-314

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Regenxbio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RGX-314

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Ma...

                            Details : RGX-314 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wet Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 17, 2020

                            Lead Product(s) : RGX-314

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RGX-314

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

                            Details : RGX-314 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wet Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 27, 2019

                            Lead Product(s) : RGX-314

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sarilumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

                            Details : Sarilumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uveitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 16, 2013

                            Lead Product(s) : Sarilumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Arman Mashayekhi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

                            Details : Ozurdex (Dexamethasone) is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.

                            Product Name : Ozurdex

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 11, 2011

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Arman Mashayekhi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : FOV2304

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Ce...

                            Details : FOV2304 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 21, 2011

                            Lead Product(s) : FOV2304

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acet...

                            Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 10, 2010

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Merck & Co

                            U.S.A arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EYE103

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

                            Details : EYE103 is a large molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Wet Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2025

                            Lead Product(s) : EYE103

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth